InMed Pharmaceuticals (INM) shares were up more than 200% pre-bell Monday following a muted session.
Vera Therapeutics (VERA) shares were 75% higher after the company said its phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy achieved its primary endpoint.
Instill Bio (TIL) shares were more than 46% higher after the company said it has appointed Jamie Freedman as chief medical officer.
Black Spade Acquisition II (BSII) stock was up 16% after the blank check company said late Friday its shareholders approved a pending business combination with The Generation Essentials Group.